| Views | |
|---|---|
| Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis | 122 |
| March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | August 2025 | September 2025 | |
|---|---|---|---|---|---|---|---|
| Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis | 3 | 12 | 2 | 2 | 4 | 3 | 0 |
| Views | |
|---|---|
| 2020_Burmester_etal.pdf | 60 |
